Tumor-to-dendritic cell reprogramming induces immunogenic lymphoid structures across cancers.

Reprogrammed tumor cells into cDC1-like cells induce immunogenic TLSs across melanoma, colon, bladder, breast, and pancreatic cancer models, including BCL6+ germinal centers.

• Why it matters: TLSs are linked to better immunotherapy outcomes, but how type 1 conventional dendritic cells drive their formation across cancers is unclear.
• What they did: The study reprogrammed tumor cells into cDC1-like cells and assessed lymphoid structure formation, cDC1-like signaling (lymphotoxin, TNF, interferon), and T-cell engagement via MHC class I and CD40.
• The result: cDC1-like cells formed imgTLSs independently of endogenous cDC1s, and their intratumoral positioning sustained local B and T responses while expanding shared clonotypes in distant untreated tumors.

AI summary of the abstract · may contain errors · not medical advice · read the paper.